From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
Treatment
Total
Pain free
N
%
Nepafenac group
106
102
96.2
Placebo group
105
71
67.6